title: Association between mitogen-activated protein kinase kinase kinase 1 rs889312 polymorphism and breast cancer risk: evidence from 59,977 subjects.
abstract: Published data on the association between mitogen-activated protein kinase kinase kinase 1 (MAP3K1) gene rs889312 polymorphism and breast cancer risk are inconclusive. To derive a more precise estimation of the relationship, a meta-analysis was performed. Crude ORs with 95% CIs were used to assess the strength of association between them. A total of seven eligible articles including 26,015 cases and 33,962 controls based on the search criteria were involved in this meta-analysis. We observed that the MAP3K1 rs889312 polymorphism was significantly correlated with breast cancer risk from the fixed effects model when all studies were pooled into the meta-analysis (the allele contrast model: OR 1.09, 95% CI 1.07-1.12; the homozygote codominant: OR 1.22, 95% CI 1.15-1.29; the heterozygote codominant: OR 1.07, 95% CI 1.04-1.11; the dominant model: OR 1.10, 95% CI 1.06-1.13; the recessive model: OR 1.18, 95% CI 1.12-1.25). No significant association was found in the BRCA1 mutation carriers in all genetic models. When stratified by BRCA2 mutation carriers status, statistically significantly elevated risk was found in this meta-analysis (C vs. A: OR 1.12, 95% CI 1.01-1.23; CC vs. AA: OR 1.35, 95% CI 1.06-1.71; the recessive model: OR 1.31, 95% CI 1.05-1.65). There was no evidence for significant association between MAP3K1 rs889312 polymorphism and breast cancer risk in BRCA1 and BRCA2 positive cohort for all comparison models. In conclusion, this meta-analysis suggests that the MAP3K1 rs889312 C allele is a low-penetrant risk factor for developing breast cancer, and there is limited evidence to indicate that MAP3K1 rs889312 polymorphism is associated with increased risk of breast cancer in BRCA1 mutation carriers.
authors.affiliation: Department of General Surgery, Wuxi People's Hospital of Nanjing Medical University, No. 299, Qingyang Road, Wuxi 214023, Jiangsu, China. lphty1_1@yahoo.com.cn
authors.forename: Pei-Hua
authors.initials: PH
authors.lastname: Lu
authors.forename: Jie
authors.initials: J
authors.lastname: Yang
authors.forename: Chen
authors.initials: C
authors.lastname: Li
authors.forename: Mu-Xin
authors.initials: MX
authors.lastname: Wei
authors.forename: Wei
authors.initials: W
authors.lastname: Shen
authors.forename: Li-ping
authors.initials: LP
authors.lastname: Shi
authors.forename: Zhi-Yang
authors.initials: ZY
authors.lastname: Jiang
authors.forename: Ning
authors.initials: N
authors.lastname: Zhou
authors.forename: Guo-Qing
authors.initials: GQ
authors.lastname: Tao
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000483:Alleles; D001943:Breast Neoplasms / Q000201:enzymology* / Q000235:genetics*; D015331:Cohort Studies; D004252:DNA Mutational Analysis; D005260:Female; D019398:Genes, BRCA1; D020022:Genetic Predisposition to Disease; D006579:Heterozygote; D006720:Homozygote; D006801:Humans; D048728:MAP Kinase Kinase Kinase 1 / Q000235:genetics*; D008875:Middle Aged; D015233:Models, Statistical; D016017:Odds Ratio; D011110:Polymorphism, Genetic; D011379:Prognosis; D012306:Risk; D012680:Sensitivity and Specificity
chemical_list: D048728:MAP Kinase Kinase Kinase 1